Pfizer, Inc. · NYSE:PFE
Pfizer — Cowen and Company 39th Annual Healthcare Conference (March 2019)
7 slides from Pfizer's conference presentation, Mar 12, 2019
Slide 1: Cowen and Company Healthcare Conference: Pfizer Oncology
Cowen and Company Healthcare Conference: Pfizer Oncology March 12, 2019 Andy Schmeltz, Chris Boshoff, M.D., Ph.D., Global President & General Chief Development Officer, Oncology, Manager, Pfizer Oncology Pfizer Global Product Development
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may include forward-looking statements about, among other things, Pfizer’s oncology in- line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, performance and potential benefits of Pfiz
Slide 3: Continued Growth and Commitment to Oncology
Continued Growth and Commitment to Oncology Advancing Our Leadership Today > 1.2M 31% patients treated with Pfizer medicines since 2006 CAGR (compound annual growth rate) in revenue from 2013-2018 18 approved cancer medicines & biosimilars LARGEST > 10K % of Pfizer investment in patients participati
Slide 4: A Focused Pfizer Oncology Vision and Strategy
A Focused Pfizer Oncology Vision and Strategy Our Commitment to Changing the Lives of People Living with Cancer 1 2 3 Extend our leadership in Advance our portfolio Lead a next wave of breast and prostate and deliver precision innovation in immunotherapy immunotherapy approaches and targeted medicin
Slide 5: Strategic Approach to Developing Breakthroughs For Patients
Strategic Approach to Developing Breakthroughs For Patients TARGETING THE TARGETING THE TUMOR TUMOR MICROENVIRONMENT SIGNALING IMMUNE NETWORKS CHECKPOINTS METABOLIC EPIGENETIC IMMUNE IMMUNE NETWORKS NETWORKS ENHANCERS ACTIVATORS INNOVATIVE MODALITIES TO DRIVE POTENTIAL FUTURE THERAPIES NCEs mAbs ADC
Slide 6: Pfizer Select NME & Programs
Pfizer Select NME & Programs Early Development Registration Intent Studies Breast Prostate Hem., Renal, Lung & IO NG-HER2 Anti-PD1 IBRANCE XTANDI DAURISMO (Biologic) IO (Biologic) PENELOPE B EMBARK AML 1L TGFβR1 CDK2/4/6 IBRANCE TALZENNA BAVENCIO (small molecule) (small molecule) PALLAS TALAPRO 1 UC
Slide 7: Q&A
Q&A
Pfizer — Cowen and Company 39th Annual Healthcare Conference (March 2019) on 6ix